Latest Insider Transactions at Biocryst Pharmaceuticals Inc (BCRX)
This section provides a real-time view of insider transactions for Biocryst Pharmaceuticals Inc (BCRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOCRYST PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOCRYST PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 15
2022
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$90,000
$18.5 P/Share
|
|
Feb 15
2022
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$15,000
$3.32 P/Share
|
|
Jan 11
2022
|
Jon P Stonehouse President & CEO |
SELL
Open market or private sale
|
Direct |
184,000
-16.95%
|
$2,760,000
$15.04 P/Share
|
|
Jan 11
2022
|
Jon P Stonehouse President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
184,000
+14.49%
|
$736,000
$4.73 P/Share
|
|
Dec 14
2021
|
Jon P Stonehouse President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
123,000
+12.0%
|
-
|
|
Dec 14
2021
|
William P Sheridan Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+40.8%
|
-
|
|
Dec 14
2021
|
Anthony Doyle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,000
+35.52%
|
-
|
|
Dec 14
2021
|
Alane P Barnes Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+25.26%
|
-
|
|
Dec 14
2021
|
Helen M. Thackray Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+23.4%
|
-
|
|
Dec 14
2021
|
Yarlagadda S Babu Chief Discovery Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+12.28%
|
-
|
|
Dec 14
2021
|
Charles K Gayer Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+32.34%
|
-
|
|
Dec 14
2021
|
Michael L Jones Exec. Director, Finance - PAO |
BUY
Grant, award, or other acquisition
|
Direct |
5,850
+34.31%
|
-
|
|
Dec 07
2021
|
Yarlagadda S Babu Chief Discovery Officer |
SELL
Open market or private sale
|
Direct |
30,100
-12.28%
|
$361,200
$12.2 P/Share
|
|
Dec 07
2021
|
Yarlagadda S Babu Chief Discovery Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
62,000
+20.19%
|
$248,000
$4.73 P/Share
|
|
Nov 30
2021
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,554
+1.93%
|
$18,648
$12.06 P/Share
|
|
Nov 30
2021
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
829
+5.04%
|
$9,948
$12.06 P/Share
|
|
Nov 30
2021
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
829
+36.26%
|
$9,948
$12.06 P/Share
|
|
Nov 30
2021
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
414
+1.24%
|
$4,968
$12.06 P/Share
|
|
Nov 24
2021
|
Vincent Milano Director |
BUY
Open market or private purchase
|
Direct |
7,500
+30.0%
|
$90,000
$12.19 P/Share
|
|
Nov 23
2021
|
Anthony Doyle Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
35,258
+27.34%
|
$423,096
$12.48 P/Share
|
|
Nov 15
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$60,000
$12.27 P/Share
|
|
Nov 15
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$15,000
$3.32 P/Share
|
|
Oct 15
2021
|
Nancy J Hutson Director |
SELL
Open market or private sale
|
Direct |
105,000
-61.74%
|
$1,575,000
$15.4 P/Share
|
|
Oct 15
2021
|
Nancy J Hutson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
105,000
+17.0%
|
$315,000
$3.24 P/Share
|
|
Sep 15
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$75,000
$15.06 P/Share
|
|
Sep 15
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$10,000
$2.63 P/Share
|
|
Sep 13
2021
|
Kenneth B Lee Jr Director |
SELL
Open market or private sale
|
Direct |
6,000
-19.83%
|
$90,000
$15.35 P/Share
|
|
Sep 13
2021
|
Kenneth B Lee Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+33.15%
|
$45,000
$3.22 P/Share
|
|
Sep 10
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
74,000
-100.0%
|
$1,110,000
$15.09 P/Share
|
|
Sep 10
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
71,000
+37.8%
|
$142,000
$2.61 P/Share
|
|
Sep 01
2021
|
Jon P Stonehouse President & CEO |
BUY
Bona fide gift
|
Indirect |
10,000
+50.0%
|
-
|
|
Sep 01
2021
|
Jon P Stonehouse President & CEO |
SELL
Bona fide gift
|
Direct |
10,000
-0.64%
|
-
|
|
Aug 31
2021
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
314
+0.96%
|
$4,710
$15.92 P/Share
|
|
Aug 31
2021
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
628
+4.07%
|
$9,420
$15.92 P/Share
|
|
Aug 31
2021
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,177
+1.5%
|
$17,655
$15.92 P/Share
|
|
Aug 31
2021
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
628
+50.0%
|
$9,420
$15.92 P/Share
|
|
Jul 15
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
5,000
-62.5%
|
$75,000
$15.69 P/Share
|
|
Jul 15
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+38.46%
|
$10,000
$2.63 P/Share
|
|
Jun 10
2021
|
Nancy J Hutson Director |
SELL
Open market or private sale
|
Direct |
23,333
-26.39%
|
$373,328
$16.86 P/Share
|
|
Jun 10
2021
|
Nancy J Hutson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,333
+12.35%
|
$69,999
$3.09 P/Share
|
|
May 28
2021
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
634
+1.94%
|
$9,510
$15.77 P/Share
|
|
May 28
2021
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
317
+2.19%
|
$4,755
$15.77 P/Share
|
|
May 28
2021
|
Nancy J Hutson Director |
BUY
Grant, award, or other acquisition
|
Direct |
317
+0.48%
|
$4,755
$15.77 P/Share
|
|
May 28
2021
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,188
+1.54%
|
$17,820
$15.77 P/Share
|
|
May 28
2021
|
William P Sheridan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
91,814
-86.38%
|
$1,377,210
$15.02 P/Share
|
|
May 28
2021
|
William P Sheridan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
91,814
+27.25%
|
$459,070
$5.26 P/Share
|
|
May 27
2021
|
William P Sheridan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
71,759
-83.21%
|
$1,076,385
$15.0 P/Share
|
|
May 27
2021
|
William P Sheridan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
71,759
+27.46%
|
$358,795
$5.26 P/Share
|
|
May 24
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
6,667
-68.97%
|
$86,671
$13.9 P/Share
|
|
May 24
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,667
+40.82%
|
$13,334
$2.63 P/Share
|